ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Structural basis for ligand reception by anaplastic lymphoma kinase
Nature
◽
10.1038/s41586-021-04141-7
◽
2021
◽
Cited By ~ 1
Author(s):
Tongqing Li
◽
Steven E. Stayrook
◽
Yuko Tsutsui
◽
Jianan Zhang
◽
Yueyue Wang
◽
...
Keyword(s):
Anaplastic Lymphoma Kinase
◽
Structural Basis
◽
Anaplastic Lymphoma
Download Full-text
Related Documents
Cited By
References
Structural basis for drug resistance mechanisms against anaplastic lymphoma kinase
Journal of Cellular Biochemistry
◽
10.1002/jcb.27437
◽
2018
◽
Vol 120
(1)
◽
pp. 768-777
◽
Cited By ~ 2
Author(s):
Sukriti Goyal
◽
Salma Jamal
◽
Asheesh Shanker
◽
Abhinav Grover
Keyword(s):
Drug Resistance
◽
Anaplastic Lymphoma Kinase
◽
Resistance Mechanisms
◽
Structural Basis
◽
Anaplastic Lymphoma
Download Full-text
Structural basis for the recognition of nucleophosmin-anaplastic lymphoma kinase oncoprotein by the phosphotyrosine binding domain of Suc1-associated neurotrophic factor-induced tyrosine-phosphorylated target-2
Journal of Structural and Functional Genomics
◽
10.1007/s10969-010-9091-x
◽
2010
◽
Vol 11
(2)
◽
pp. 125-141
◽
Cited By ~ 4
Author(s):
Seizo Koshiba
◽
Hua Li
◽
Yoko Motoda
◽
Tadashi Tomizawa
◽
Takuma Kasai
◽
...
Keyword(s):
Neurotrophic Factor
◽
Anaplastic Lymphoma Kinase
◽
Binding Domain
◽
Structural Basis
◽
Anaplastic Lymphoma
◽
Phosphotyrosine Binding Domain
Download Full-text
Regulated expression of the Anaplastic Lymphoma Kinase (ALK) in cultured rat hepatic stellate cells during transdifferentiation into myofibroblasts
Zeitschrift für Gastroenterologie
◽
10.1055/s-2005-861584
◽
2005
◽
Vol 43
(01)
◽
Author(s):
M Antoine
◽
CG Tag
◽
W Wirz
◽
M Mavituna
◽
AM Gressner
◽
...
Keyword(s):
Hepatic Stellate Cells
◽
Anaplastic Lymphoma Kinase
◽
Stellate Cells
◽
Anaplastic Lymphoma
◽
Regulated Expression
Download Full-text
Anaplastic Lymphoma Kinase in Human Cancer
Critical Reviews™ in Oncogenesis
◽
10.1615/critrevoncog.v17.i2.10
◽
2012
◽
Vol 17
(2)
◽
pp. 123-143
◽
Cited By ~ 5
Author(s):
Christina Schonherr
◽
Bengt Hallberg
◽
Ruth Palmer
Keyword(s):
Anaplastic Lymphoma Kinase
◽
Human Cancer
◽
Anaplastic Lymphoma
Download Full-text
Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)
Case Medical Research
◽
10.31525/ct1-nct04009317
◽
2019
◽
Author(s):
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Anaplastic Lymphoma Kinase
◽
Small Cell
◽
Line Treatment
◽
Small Cell Lung
◽
First Line
◽
Anaplastic Lymphoma
◽
Alk Positive
◽
First Line Treatment
Download Full-text
Faculty Opinions recommendation of Anaplastic lymphoma kinase spares organ growth during nutrient restriction in Drosophila.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.12593957.791402800
◽
2012
◽
Author(s):
Savraj Grewal
Keyword(s):
Anaplastic Lymphoma Kinase
◽
Nutrient Restriction
◽
Organ Growth
◽
Anaplastic Lymphoma
Download Full-text
Faculty Opinions recommendation of The anaplastic lymphoma kinase in the pathogenesis of cancer.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.13353985.14725086
◽
2011
◽
Author(s):
Ruth Palmer
Keyword(s):
Anaplastic Lymphoma Kinase
◽
Anaplastic Lymphoma
Download Full-text
Faculty Opinions recommendation of Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.12934957.14822055
◽
2012
◽
Author(s):
John Proudfoot
Keyword(s):
Drug Design
◽
Anaplastic Lymphoma Kinase
◽
Dual Inhibitor
◽
Structure Based Drug Design
◽
Anaplastic Lymphoma
◽
Mesenchymal Epithelial Transition Factor
◽
Factor C
◽
Mesenchymal Epithelial Transition
Download Full-text
Faculty Opinions recommendation of Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.12934957.14323054
◽
2011
◽
Author(s):
John Lowe
Keyword(s):
Drug Design
◽
Anaplastic Lymphoma Kinase
◽
Dual Inhibitor
◽
Structure Based Drug Design
◽
Anaplastic Lymphoma
◽
Mesenchymal Epithelial Transition Factor
◽
Factor C
◽
Mesenchymal Epithelial Transition
Download Full-text
Faculty Opinions recommendation of Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.718242031.793491637
◽
2014
◽
Author(s):
Jürgen Bajorath
Keyword(s):
Anaplastic Lymphoma Kinase
◽
Selective Inhibitors
◽
Anaplastic Lymphoma
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close